litlas
Log inCreate account

Daniel Morgensztern

Active 2005–2026

81
Papers
18,833
Citations
44
h-index
73
i10-index

Citations

Citations per year for Daniel Morgensztern1993: 1 citations2000: 3 citations2001: 1 citations2006: 7 citations2007: 24 citations2008: 29 citations2009: 25 citations2010: 26 citations2011: 31 citations2012: 28 citations2013: 23 citations2014: 33 citations2015: 42 citations2016: 70 citations2017: 80 citations2018: 85 citations2019: 533 citations2020: 733 citations2021: 873 citations2022: 797 citations2023: 655 citations2024: 1,257 citations2025: 600 citations2026: 20 citations1994–1999: no citations, so these years are not shown2002–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,404 citing papers, 28.8% of this breakdownUnited States: 1,729 citing papers, 20.7% of this breakdownItaly: 367 citing papers, 4.4% of this breakdownUnited Kingdom: 310 citing papers, 3.7% of this breakdownJapan: 307 citing papers, 3.7% of this breakdownGermany: 272 citing papers, 3.2% of this breakdownSpain: 260 citing papers, 3.1% of this breakdownFrance: 239 citing papers, 2.9% of this breakdownCanada: 216 citing papers, 2.6% of this breakdownSouth Korea: 214 citing papers, 2.6% of this breakdownNetherlands: 164 citing papers, 2% of this breakdownIndia: 152 citing papers, 1.8% of this breakdown
0%28.8%Other 20.5%

Institutions

Fields

  • Medicine65.9%
  • Biochemistry, Genetics and Molecular Biology27.3%
  • Immunology and Microbiology2.6%
  • Engineering1%
  • Computer Science0.6%
  • Chemistry0.5%
  • Other2.1%

Topics

  • Lung Cancer Treatments and Mutations9.8%
  • Lung Cancer Research Studies8.9%
  • Lung Cancer Diagnosis and Treatment5.7%
  • Cancer Immunotherapy and Biomarkers5.2%
  • Neuroendocrine Tumor Research Advances3.2%
  • Cancer Genomics and Diagnostics2.8%
  • Other64.4%

Coauthors

All papers

Open in search
  1. The biology and management of non-small cell lung cancer

    Authors: Roy S. Herbst, Daniel Morgensztern, Chris Boshoff - Nature 2018 cited by 5,055

  2. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip Pravin Patel, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2022 cited by 1,419

  3. NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2023 cited by 483

  4. Non–Small Cell Lung Cancer, Version 4.2024

    Authors: Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm M. DeCamp, Aakash Desai, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Jonathan W. Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Lisa Hang - Journal of the National Comprehensive Cancer Network 2024 cited by 756

  5. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Christine M. Lovly, Renato Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2021 cited by 1,006

  6. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

    Authors: Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel - The Lancet Oncology 2016 cited by 553

  7. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    Authors: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 114

  8. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

    Authors: D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly - Journal of Clinical Oncology 2022 cited by 104

  9. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

    Authors: Taofeek K. Owonikoko, Keunchil Park, Ramaswamy Govindan, Neal Ready, Martin Reck, Solange Peters, Shaker R. Dakhil, Alejandro Navarro, Jerónimo Rafael Rodríguez‐Cid, Michael Schenker, Jong Seok Lee, Vanesa Gutiérrez, Ivor Percent, Daniel Morgensztern, Carlos H. Barrios, Laurent Greillier, Sofia Baka, Miten Patel, Wen Lin, Giovanni Selvaggi, Christine Baudelet, Jonathan Baden, Dimple Pandya, Parul Doshi, Hye Ryun Kim - Journal of Clinical Oncology 2021 cited by 267

  10. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

    Authors: Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone - Clinical Cancer Research 2019 cited by 322

  11. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

    Authors: Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian J. Hochmair, Mark M. Awad, Michael Thomas, Glenwood Goss, Paul Wheatley‐Price, Frances A. Shepherd, Marie Florescu, Parneet Cheema, Quincy S. Chu, Sang‐We Kim, Daniel Morgensztern, Melissa L. Johnson, Sophie Cousin, Dong‐Wan Kim, Mor Moskovitz, David Vicente, Boaz E. Aronson, Rosalind Hobson, Helen J. Ambrose, Sajan Khosla, Avinash Reddy, Deanna L. Russell, Mohamed Reda Keddar, James Conway, J. Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J. Jewsbury, Sonia Iyer, Simon T. Barry, Jan Cosaert, John V. Heymach - Nature Medicine 2024 cited by 116

  12. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

    Authors: Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William L. Read, Ryan M. Tierney, Anna Vlahiotis, Edward L. Spitznagel, Jay F. Piccirillo - Journal of Clinical Oncology 2006 cited by 1,851

  13. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

    Authors: D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett E. Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip Komarnitsky, Karen Kelly - Clinical Cancer Research 2021 cited by 77

  14. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

    Authors: Bryan Oronsky, C. Patrick, Daniel Morgensztern, Corey A. Carter - Neoplasia 2017 cited by 760

  15. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

    Authors: David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Paolo Scaglioni, Song Zhang, Marilyn M. Li, David T. Weaver, Louis Vaikus, Mitchell Keegan, Joanna Horobin, Timothy F. Burns - Lung Cancer 2019 cited by 182

  16. Non–small-cell Lung Cancer With Brain Metastasis at Presentation

    Authors: Saiama N. Waqar, Pamela Samson, Clifford G. Robinson, Jeffrey D. Bradley, Siddhartha Devarakonda, Lingling Du, Ramaswamy Govindan, Feng Gao, Varun Puri, Daniel Morgensztern - Clinical Lung Cancer 2018 cited by 253

  17. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).

    Authors: Martin Wermke, Enriqueta Felip, Yasutoshi Kuboki, Daniel Morgensztern, Cyrus Sayehli, Miguel F. Sanmamed, Edurne Arriola, Zohra Oum'Hamed, Eric Song, Matus Studeny, Valentina Gambardella - Journal of Clinical Oncology 2023 cited by 49

  18. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers

    Authors: Siddhartha Devarakonda, Yize Li, Fernanda Martins Rodrigues, Sumithra Sankararaman, Humam Kadara, Chandra Goparaju, Irena Lanc, Kymberlie Pepin, Saiama N. Waqar, Daniel Morgensztern, Jeffrey Ward, Ashiq Masood, Robert Fulton, Lucinda Fulton, Michael A. Gillette, Shankha Satpathy, Steven A. Carr, Ignacio Wistuba, Harvey Pass, Richard K. Wilson, Li Ding, Ramaswamy Govindan - Journal of Clinical Oncology 2021 cited by 110

  19. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

    Authors: John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly - Journal of Clinical Oncology 2018 cited by 139

  20. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

    Authors: Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum’ Hamed, Meiruo Liu, Matus Studeny, Taofeek K. Owonikoko - Future Oncology 2022 cited by 64

  21. Genomic alterations in lung adenocarcinoma

    Authors: Siddhartha Devarakonda, Daniel Morgensztern, Ramaswamy Govindan - The Lancet Oncology 2015 cited by 414

  22. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

    Authors: Alex H. Wagner, Siddhartha Devarakonda, Zachary L. Skidmore, Kilannin Krysiak, Avinash Ramu, Lee Trani, Jason Kunisaki, Ashiq Masood, Saiama N. Waqar, Nicholas C. Spies, Daniel Morgensztern, Jason Waligorski, Jennifer Ponce, Robert S. Fulton, Leonard B. Maggi, Jason D. Weber, Mark A. Watson, Christopher J. O’Conor, Jon H. Ritter, Rachelle R. Olsen, Haixia Cheng, Anandaroop Mukhopadhyay, İsmail Can, Melissa H. Cessna, Trudy G. Oliver, Elaine R. Mardis, Richard K. Wilson, Malachi Griffith, Obi L. Griffith, Ramaswamy Govindan - Nature Communications 2018 cited by 169

  23. A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

    Authors: Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan M. Lehman, Daniel Morgensztern, Jyoti D. Patel, John M. Wrangle, Giuseppe Curigliano, Laurent Greillier, Melissa L. Johnson, Neal Ready, G. Robinet, Satwant Lally, David Maag, Ricardo Santoyo Valenzuela, Vincent Blot, Benjamin Besse - Journal of Thoracic Oncology 2021 cited by 77

  24. Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

    Authors: Anthony W. Tolcher, Wungki Park, Judy S. Wang, Alexander I. Spira, Pasi A. Jänne, Ho‐Jin Lee, Stanley C. Gill, Patricia LoRusso, Benjamin Herzberg, Jonathan W. Goldman, Daniel Morgensztern, Jordan Berlin, Anup Kasi, Hisaki Fujii, Meredith Pelster - Journal of Clinical Oncology 2023 cited by 32